Patents Assigned to KINNATE BIOPHARMA INC.
  • Treatment of cancer with a RAF inhibitor
    Patent number: 11918587
    Abstract: Provided herein are compositions and methods for the treatment of a cancer. Said compositions comprise a RAF inhibitor. Some embodiments comprise combination therapy featuring the RAF inhibitor with at least one oncology therapeutic agent.
    Type: Grant
    Filed: April 6, 2023
    Date of Patent: March 5, 2024
    Assignee: KINNATE BIOPHARMA INC.
    Inventors: Aleksandra Franovic, Eric Martin, Nichol L. G. Miller, Eric Murphy, Richard Thomas Williams, Ken Kobayashi
  • Inhibtors of Raf kinases
    Patent number: 11814384
    Abstract: Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Grant
    Filed: February 3, 2023
    Date of Patent: November 14, 2023
    Assignee: KINNATE BIOPHARMA INC.
    Inventors: Toufike Kanouni, Jason M. Cox, John Tyhonas, Robert S. Kania, Subhas J. Chakravorty, Young K. Chen
  • Inhibitors of MEK kinase
    Patent number: 11780862
    Abstract: Provided herein are inhibitors of MEK kinase, pharmaceutical compositions comprising said inhibitory compounds, and methods for using said MEK kinase inhibitory compounds for the treatment of disease.
    Type: Grant
    Filed: February 27, 2023
    Date of Patent: October 10, 2023
    Assignee: KINNATE BIOPHARMA INC.
    Inventors: Toufike Kanouni, Robert S. Kania, Jason M. Cox
  • Inhibitors of MET kinase
    Patent number: 11753395
    Abstract: Provided herein are inhibitors of MET receptor tyrosine kinase, pharmaceutical compositions comprising said inhibitory compounds, and methods for using said MET kinase inhibitory compounds for the treatment of disease.
    Type: Grant
    Filed: December 14, 2022
    Date of Patent: September 12, 2023
    Assignee: KINNATE BIOPHARMA INC.
    Inventors: Xiaohu S. Ouyang, Toufike Kanouni, John S. Tyhonas, Jason M. Cox, Robert S. Kania
  • Inhibtors of RAF kinases
    Patent number: 11746095
    Abstract: Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Grant
    Filed: May 6, 2022
    Date of Patent: September 5, 2023
    Assignee: KINNATE BIOPHARMA INC.
    Inventors: Stephen W. Kaldor, Toufike Kanouni, Eric Murphy, Jason Cox, Robert Kania
  • Inhibitors of RAF kinases
    Patent number: 11667634
    Abstract: Provided herein are heteroaryl inhibitors of receptor tyrosine kinase effector (RAF), pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of disease.
    Type: Grant
    Filed: February 4, 2021
    Date of Patent: June 6, 2023
    Assignee: KINNATE BIOPHARMA INC.
    Inventors: Stephen W. Kaldor, Toufike Kanouni, Lee Arnold
  • Inhibitors of RAF kinases
    Patent number: 11407737
    Abstract: Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Grant
    Filed: September 16, 2021
    Date of Patent: August 9, 2022
    Assignee: KINNATE BIOPHARMA INC.
    Inventors: Stephen W. Kaldor, Toufike Kanouni, John Tyhonas, Eric Murphy, Jason Cox, Robert Kania
  • Inhibitors of cyclin-dependent kinases
    Patent number: 11390618
    Abstract: Provided herein are inhibitors of cyclin-dependent kinases (CDKs), pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Grant
    Filed: November 11, 2020
    Date of Patent: July 19, 2022
    Assignee: KINNATE BIOPHARMA INC.
    Inventors: Toufike Kanouni, Lee D. Arnold, Stephen W. Kaldor, Eric A. Murphy, John Tyhonas
  • Inhibitors of RAF kinases
    Patent number: 11377431
    Abstract: Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Grant
    Filed: October 11, 2021
    Date of Patent: July 5, 2022
    Assignee: KINNATE BIOPHARMA INC.
    Inventors: Stephen W. Kaldor, Toufike Kanouni, Eric Murphy, Jason Cox, Robert Kania
  • Inhibitors of cyclin-dependent kinases
    Patent number: 11358958
    Abstract: Provided herein are inhibitors of cyclin-dependent kinases (CDKs), pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Grant
    Filed: November 11, 2020
    Date of Patent: June 14, 2022
    Assignee: KINNATE BIOPHARMA INC.
    Inventors: Toufike Kanouni, Lee D. Arnold, Stephen W. Kaldor, Eric A. Murphy, John Tyhonas
  • Inhibitors of fibroblast growth factor receptor kinases
    Patent number: 11345681
    Abstract: Provided herein are heteroaryl inhibitors of fibroblast growth factor receptor kinases, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Grant
    Filed: June 4, 2021
    Date of Patent: May 31, 2022
    Assignee: KINNATE BIOPHARMA INC.
    Inventors: Stephen W. Kaldor, John Tyhonas, Eric A. Murphy, Toufike Kanouni, Lee D. Arnold, Robert Kania, Jason M. Cox
  • Inhibitors of RAF kinases
    Patent number: 11098031
    Abstract: Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Grant
    Filed: October 23, 2020
    Date of Patent: August 24, 2021
    Assignee: KINNATE BIOPHARMA INC.
    Inventors: Stephen W. Kaldor, Toufike Kanouni, John Tyhonas, Eric Murphy
  • Inhibitors of RAF kinases
    Patent number: 10927111
    Abstract: Provided herein are heteroaryl inhibitors of receptor tyrosine kinase effector (RAF), pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of disease.
    Type: Grant
    Filed: April 30, 2020
    Date of Patent: February 23, 2021
    Assignee: KINNATE BIOPHARMA INC.
    Inventors: Stephen W. Kaldor, Toufike Kanouni, Lee Arnold
  • Inhibitors of cyclin-dependent kinases
    Patent number: 10894788
    Abstract: Provided herein are inhibitors of cyclin-dependent kinases (CDKs), pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: January 19, 2021
    Assignee: KINNATE BIOPHARMA INC.
    Inventors: Toufike Kanouni, Lee D. Arnold, Stephen W. Kaldor, Eric A. Murphy, John Tyhonas